LGND - ASCO 2022: Surprising News in Cancer Research
The American Society of Clinical Oncology (ASCO) held its annual meeting this week, and it's a must-show event for anybody pursuing cancer therapies. Our mini-roundtable has been digging into some of the presentations, and we found a few companies announcing nice surprises, among them, Adaptive Biotechnologies (NASDAQ: ADPT) , Legend Biotech (NASDAQ: LGND) , and Arcellx (NASDAQ: ACLX) .
Here's what these biotechs revealed this week.
Taylor Carmichael (Adaptive Biotechnologies): Because the biotech industry is highly secretive, Adaptive Biotechnologies often can't talk about what companies are using its technology. At ASCO, however, the scientists (and investors) want to trust the data they're being shown, so a lot of researchers were noting that they used Adaptive's test for minimum residual disease (MRD) in blood cancers. That offers investors a peek at some of the researchers who are using Adaptive's solution.
For further details see:
ASCO 2022: Surprising News in Cancer Research